EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NovaBay Pharmaceuticals's enterprise value is $4.09 Mil.
NovaBay Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $14.73 Mil. Therefore, NovaBay Pharmaceuticals's EV-to-Revenue for today is 0.28.
The historical rank and industry rank for NovaBay Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
NBY'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.08 Med: 2.22 Max: 32.04
Current: 0.28
During the past 13 years, the highest EV-to-Revenue of NovaBay Pharmaceuticals was 32.04. The lowest was 0.08. And the median was 2.22.
NBY's EV-to-Revenue is ranked better than 90.49% of 1031
companies
in the Biotechnology industry
Industry Median: 7.58
vs NBY: 0.28
As of today (2024-04-19), NovaBay Pharmaceuticals's stock price is $0.0824.
NovaBay Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.02. Therefore, NovaBay Pharmaceuticals's PS Ratio for today is 0.02.
NovaBay Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for NovaBay Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovaBay Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
2.27
1.78
1.15
0.25
0.26
NovaBay Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
0.25
0.33
0.26
0.30
0.26
Competitive Comparison
For the Biotechnology subindustry, NovaBay Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovaBay Pharmaceuticals EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where NovaBay Pharmaceuticals's EV-to-Revenue falls into.
NovaBay Pharmaceuticals's current Enterprise Value is $4.09 Mil.
NovaBay Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBay Pharmaceuticals's share price for today is $0.0824.
NovaBay Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBay Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBY has been successfully added to your 